09:02 AM EDT, 08/05/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) paid China-based CSPC Pharmaceutical Group $10 million for the exercise of a license option for one of the pre-clinical candidate programs under their strategic research collaboration agreement. The agreement covers the discovery and development of novel oral small molecule candidates for multiple targets as chosen by the British drugmaker, according to a Wednesday release.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.